Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024
September 05 2024 - 12:00AM
UK Regulatory
Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial
Results on September 12, and to Host KOL Event on September 30,
2024
Vivoryon Therapeutics N.V. to Report Half
Year 2024 Financial Results on September 12, and to Host KOL Event
on September 30, 2024
Halle (Saale) / Munich, Germany,
September 5, 2024 - Vivoryon Therapeutics
N.V. (Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that it will host two events in
September:
- Half year 2024 results on September 12; webcast at 3pm
CEST
- Virtual Kidney Disease KOL event on September 30, 2024; webcast
at 3pm CEST
Half Year 2024 Results
Vivoryon will publish its financial results for the half year 2024
and provide a corporate update on Thursday, September 12, 2024. The
Company will host a conference call and webcast open to the public.
The report will be available for download on the Company's website
https://www.vivoryon.com/financial-information/.
Conference call details
Date: September 12, 2024
Time: 3:00 pm CEST / 9:00 am EDT
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon’s
website at:
https://www.vivoryon.com/news-and-events/presentations-webcasts/
To join the conference call via phone,
participants may pre-register and will receive dedicated dial-in
details to easily and quickly access the call via the following
website:
https://register.vevent.com/register/BIb82f5f65fffe4d5faaade135258da32a
It is suggested participants dial into the
conference call 15 minutes prior to the scheduled start time to
avoid any delays in attendance.
Virtual Kidney Disease KOL
Event
Vivoryon will host a virtual Kidney Disease KOL (Key Opinion
Leaders) webcast on Monday, September 30, 2024.
Conference call details
Date: September 30, 2024
Time: 3:00 pm CEST / 9:00 am EDT
Further details of the event and participation
information will be made available on the Company’s website in due
time.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology
company focused on developing innovative small molecule-based
medicines. Driven by its passion for ground-breaking science and
innovation, the Company strives to change the lives of patients in
need suffering from severe diseases. The Company leverages its
in-depth expertise in understanding post-translational
modifications to develop medicines that modulate the activity and
stability of proteins which are altered in disease settings. The
Company has established a pipeline of orally available small
molecule inhibitors for various indications including Alzheimer’s
disease, inflammatory and fibrotic disorders, including of the
kidney, and cancer. www.vivoryon.com.
Vivoryon Forward Looking
Statements
This press release includes forward-looking statements,
including, without limitation, those regarding the business
strategy, management plans and objectives for future operations of
Vivoryon Therapeutics N.V. (the “Company”), estimates and
projections with respect to the market for the Company’s products
and forecasts and statements as to when the Company’s products may
be available. Words such as “anticipate,” “believe,” “estimate,”
“expect,” “forecast,” “intend,” “may,” “plan,” “project,”
“predict,” “should” and “will” and similar expressions as they
relate to the Company are intended to identify such forward-looking
statements. These forward-looking statements are not guarantees of
future performance; rather they are based on the Management’s
current expectations and assumptions about future events and
trends, the economy and other future conditions. The
forward-looking statements involve a number of known and unknown
risks and uncertainties. These risks and uncertainties and other
factors could materially adversely affect the outcome and financial
effects of the plans and events described herein. The Company’s
results of operations, cash needs, financial condition, liquidity,
prospects, future transactions, strategies or events may differ
materially from those expressed or implied in such forward-looking
statements and from expectations. As a result, no undue reliance
should be placed on such forward-looking statements. This press
release does not contain risk factors. Certain risk factors that
may affect the Company’s future financial results are discussed in
the published annual financial statements of the Company. This
press release, including any forward-looking statements, speaks
only as of the date of this press release. The Company does not
assume any obligation to update any information or forward-looking
statements contained herein, save for any information required to
be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
Vivoryon Therapeutics Nv (LSE:0R3M)
Historical Stock Chart
From Nov 2024 to Dec 2024
Vivoryon Therapeutics Nv (LSE:0R3M)
Historical Stock Chart
From Dec 2023 to Dec 2024
